Finally, Wedbush upped their target price on shares of Unity Biotechnology to $36.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 2nd. HC Wainwright cut their target price on Unity Biotechnology from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, November 9th. Mizuho lowered their target price on shares of Unity Biotechnology from $80.00 to $12.00 and set a "buy" rating for the company in a report on Wednesday, November 16th. Analyst Ratings Changes Several equities analysts have recently issued reports on the stock. Unity Biotechnology has a twelve month low of $2.09 and a twelve month high of $18.50. The company's 50-day moving average is $3.61 and its two-hundred day moving average is $4.45. The company has a market cap of $64.14 million, a P/E ratio of -0.56 and a beta of 0.80. The company has a debt-to-equity ratio of 0.17, a current ratio of 6.12 and a quick ratio of 6.12. The company had a trading volume of 135,642 shares, compared to its average volume of 287,267. Shares of Unity Biotechnology stock traded up $0.13 during trading hours on Monday, hitting $4.52. Get Unity Biotechnology alerts: Unity Biotechnology Stock Up 3.0 % State Street Corp now owns 172,640 shares of the company's stock valued at $68,000 after purchasing an additional 42,200 shares during the last quarter. Finally, State Street Corp boosted its holdings in Unity Biotechnology by 32.4% in the third quarter. purchased a new stake in Unity Biotechnology during the 3rd quarter worth $64,000. Connor Clark & Lunn Investment Management Ltd. Maven Securities LTD acquired a new position in Unity Biotechnology during the 3rd quarter worth approximately $40,000.
Virtu Financial LLC now owns 62,640 shares of the company's stock worth $35,000 after purchasing an additional 12,681 shares during the period. Virtu Financial LLC boosted its position in Unity Biotechnology by 25.4% during the 2nd quarter. Prime Capital Investment Advisors LLC purchased a new position in Unity Biotechnology during the fourth quarter worth $31,000. Hedge Funds Weigh In On Unity BiotechnologyĪ number of large investors have recently made changes to their positions in UBX. Based on an average daily volume of 261,800 shares, the short-interest ratio is presently 2.9 days. Currently, 5.6% of the company's shares are short sold. As of January 31st, there was short interest totalling 761,600 shares, an increase of 19.6% from the January 15th total of 636,700 shares. (NASDAQ:UBX – Get Rating) saw a large increase in short interest during the month of January.
0 kommentar(er)
